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Alpha-KlothoBackground: Acromegaly is an illness usually deﬁned by excessively high growth hormone (GH) and insu-
lin like growth factor 1 (IGF-1) levels, the latter mainly reﬂecting GH action on the liver. IGF-1, also
known as somatomedin C, mediates several actions of GH. The diagnosis and management of acromegaly
is relatively straight forward, but long-term follow-up of patients can be difﬁcult, as elevated IGF-1 levels
can occur in the presence of apparently normalised GH levels and late recurrence of acromegaly may
arise despite previous suppression on oral glucose tolerance testing. Data suggest this applies especially
to patients in whom the GH receptor lacks exon 3. In such patients, GH may not always be a useful mar-
ker of disease, and traditional GH cut-offs may be misleading. Recent data suggest that soluble Klotho
(sKlotho), besides and in addition to IGF-1, may help monitor the activity of GH-producing adenomas
(presumably reﬂecting GH action on the kidneys) and may be a useful supplementary tool.
Methods: GHR genotyping was performed in 112 patients with acromegaly. IGF-1 and sKlotho levels were
measured in the sera of patients before and after transsphenoidal surgery, with emphasis on patients
judged inconclusively cured by surgery orwith small residual tumourmasses shortly after surgery. Patients
were assessed for recurrence of acromegaly with GH levels (random or nadir during an oGTT).
Results: Of the 48patientswhounderwent surgery between2000 and 2009 andwhohadwell-documented
longer term follow-up at our institution, 29 had no biochemical evidence of residual disease activity after
transsphenoidal surgery (marked reduction in IGF-1 and sKlotho levels, GH suppressible to <1 ng/ml) and
were classiﬁed as in remission. 2 of these patients developed recurrent symptoms of acromegaly during
follow-upwith increasing levels of IGF-1 and sKlotho, and both patients were carriers of the d3-GHR geno-
type.
Conclusions: Acromegalic patients with the d3-GHR polymorphismmight be – for a given low postsurgical
GH level – at higher risk for recurrence andmay require a lower GH nadir during oGTT to be classiﬁed as in
remission. Soluble Klotho could be useful in the follow-up of acromegalic patients. The question arises
whether sKlotho not only reﬂects the activity of GH-secreting pituitary adenomas but whether Klotho
(ectodomain clipping?) could also mediate selected actions of GH.
 2013 The Authors. Published by Elsevier Inc. Open access under CC BY license.1. Introduction
The growth hormone receptor (GHR) is expressed in many tis-
sues and mediates the effect of growth hormone (GH), which is
of great importance for skeletal growth and the attainment of adult
height. GH secretion by pituitary somatotropic cells is mainly reg-
ulated by hypothalamic neuro-endocrine mediators such as
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such as ghrelin and by feedback inhibition via insulin like growth
factor 1 (IGF-1). There has been a lot of interest in the GHR geno-
type in recent years, after it was found that there are two main iso-
forms of GHR in humans, a full-length isoform (ﬂ-GHR) and an
isoform that lacks exon 3 (d3-GHR). This species-speciﬁc expres-
sion pattern is due to two distinct GHR transcripts, characterized
by retention or exclusion of exon 3, respectively (Pantel et al.,
2000). The d3-GHR polymorphism occurs in the heterozygous state
in 30–40% and in the homozygous state in 10–20% of the popula-
tion, while the remaining half of the population is homozygous
for the ﬂ isoform (Dos Santos et al., 2004). Exon 3 encodes for a part
of the extracellular, ligand-binding domain of the GHR. Although
wild type ﬂ-GHR and mutant d3-GHR have comparable in vitro
GH-binding properties, d3-GHR displays a greater response to GH
stimulation. At any given GH level, enhanced intracellular signal
transduction with increased transcriptional activity on target
genes has been observed, with the transduction of GH signalling
being approximately 30% higher in both d3-GHR homodimers
and d3/ﬂ-GHR heterodimers than in ﬂ-GHR homodimers (Dos San-
tos et al., 2004). The signiﬁcance of the d3-GHR in patients with
growth hormone disorders remains unclear and is of particular
interest.
The klotho gene was discovered in a mouse model in 1997 after
its accidental disruption (by insertion of ectopic DNA) caused a
phenotype of accelerated aging (Kuro-o et al., 1997). Later, it was
found that aging suppression and lifespan extension could be
achieved in mice by overexpression of Klotho (Kurosu et al.,
2005). Klotho is the goddess of fate, ‘spinning the thread of life’
in Greek mythology. Mice with deﬁcient Klotho expression have
a shorter life span and premature skin atrophy, osteoporosis, hypo-
gonadotropic hypogonadism, arteriosclerosis, pulmonary emphy-
sema and neuro-degenerative disorders. The klotho gene encodes
a single-pass transmembrane protein (1014 amino acids) with a
short cytoplasmic domain (10 amino acids) and an extracellular
domain composed of two beta-glycosidase-like tandem repeats
(KL1, KL2) and is predominantly expressed in kidneys, choroid
plexus and several endocrine organs including the pituitary, the
parathyroids, the pancreas, and reproductive organs (gonads, pla-
centa) (Kuro-o et al., 1997; Li et al., 2004). The function of the Klo-
tho protein remained an enigma for years but in 2006, two
independent groups reported that membrane Klotho served as a
co-receptor for ﬁbroblast growth factor 23 (FGF23, a hormone pro-
duced by osteocytes which inhibits renal phosphate reabsorption
and calcitriol production) and thereby plays an important role in
phosphate homeostasis (Kurosu et al., 2006; Urakawa et al.,
2006). Klotho protein also exists in a soluble form which can arise
either from a distinct transcript or from secretase-catalyzed ecto-
domain shedding of membrane Klotho (Imura et al., 2004; Mat-
sumura et al., 1998). It is released into the extracellular space
and soluble Klotho (sKlotho) can reach and affect a number of tar-
get tissues and processes, including regulation of hormone and
growth factor (e.g. inhibition of insulin/IGF-1) signalling, and of
ion channel and transporter plasma membrane abundance and
activity, e.g. to attenuate calciuria. Currently, sKlotho should not
be labelled as a hormone since cognate receptors have not been
identiﬁed thus far. However, circulating sKlotho can regulate bio-
logical processes, e.g. by (enzymatic) glycan modiﬁcation. Illustrat-
ing an action on the nephron, sKlotho prevents endocytosis of
transient receptor potential cation channel, subfamily V, member
5 (TRPV5) (Chang et al., 2005). The increase in retention time on
the plasma membrane enhances ion channel activity and thereby
decreases renal calcium loss (Alexander et al., 2009; Asai et al.,
2012). The soluble form which is released into the circulation can
be detected by an ELISA (Yamazaki et al., 2010). Levels of sKlotho
decrease with age in healthy subjects and are inversely relatedwith mortality in the elderly (Yamazaki et al., 2010; Semba et al.,
2011). The kidneys appear to be the major source of sKlotho in sera
of human subjects; accordingly, serum sKlotho decreased by about
40% following nephrectomy in living donors (Akimoto et al., 2013).
Although renal expression of the Klotho gene and urinary Klotho
levels have been found to be decreased in renal disease, it currently
remains controversial whether plasma sKlotho is a useful bio-
marker for kidney disease (Asai et al., 2012; Koh et al., 2001; Akim-
oto et al., 2012; Hu et al., 2011).
Acromegaly leads to high serum phosphate and FGF23 levels
despite enhanced GFR, as well as to insulin resistance and hyper-
glycaemia (Ito et al., 2007). As Klotho levels may relate to FGF23
and insulin resistance (or high phosphate and glucose, respec-
tively) in acromegaly, it is of particular interest in these patients,
and we therefore measured sKlotho in sera of patients before and
after transsphenoidal surgery.2. Effect of the d3-GHR in healthy subjects
It is important to note that as long as normal GH secretion and
an intact feedback mechanism are present, potential variations in
GH sensitivity due to GHR differences can be compensated by
endogenous pituitary GH secretion. The extracellular fragment of
the GHR is cleaved from the cell surface and circulates as a GH
binding protein (GHBP). GHBP prolongs the plasma half-life of cir-
culating GH. Wan et al. recently reported that the GHR exon 3 poly-
morphism could be assessed not only by DNA analysis but also by
protein analysis of serum samples using an ELISA measuring total
and exon 3-positive GHBP. Subjects with the ﬂ/ﬂ genotype (all
GHBP molecules exon 3-positive) had higher levels of total GHBP
in serum, followed by those with the d3/ﬂ genotype, whereas those
with the d3/d3 genotype (all GHBPmolecules exon 3-negative) had
the lowest total GHBP levels (Wan et al., 2013). It has, however, not
been formally tested whether the GHR isoform has an inﬂuence on
(GHR-mediated?) clearance of GH from the circulation.3. Effect of the d3-GHR in a pediatric population with growth
deﬁciency
In children with GH deﬁciency, replacement therapy is a widely
accepted and efﬁcient treatment option. As the d3-GHR polymor-
phism could affect the response to GH therapy, various subgroups
of children with growth deﬁciency have been investigated. In their
original work, Dos Santos and co-authors found that children car-
rying an allele encoding the d3-GHR variant were more responsive
(in terms of growth) to GH administration than children homozy-
gous (ﬂ/ﬂ) for the wild type GHR (Dos Santos et al., 2004). These
ﬁndings were conﬁrmed by some studies but were challenged by
others, who found no impact of the d3-GHR allele on the response
to GH treatment and concluded that the effect of the d3-GHR allele
on responsiveness to GH therapy is controversial (Blum et al.,
2006).
As mentioned above, variations in sensitivity to GH may be
irrelevant as long as compensation by endogenous GH secretion
works well. This should be kept in mind when discussing several
studies on GH therapy to stimulate growth where an inﬂuence of
the GHR genotype might be expected, especially when low doses
of GH are given to patients with severe GH deﬁciency. These ﬁnd-
ings generally have limited consequences in clinical practice as GH
doses during treatment are adjusted according to their effects on
IGF-1 and especially the growth of a child (and not according to
the GHR polymorphism). Therefore, a recent editorial concluded
that GHR genotyping has a limited impact in clinical medicine
(Bougneres, 2010).
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in acromegaly
The diagnosis of acromegaly is generally straightforward, as
long as clinicians are aware of this possibility. Patients have typical
signs and symptoms and elevated GH and IGF-1, the marker and
mediator of GH actions, on blood testing. The diagnosis is con-
ﬁrmed by non-suppressible GH levels (nadir >1 ng/ml) during oral
glucose tolerance testing (oGTT). The distribution of the GHR iso-
forms in various acromegaly cohorts has been found to be compa-
rable to that seen in the general population. Consistent with the
ﬁnding that the d3-GHR shows enhanced GH signal transduction,
acromegalic patients carrying (at least one) d3-GHR allele, on aver-
age, appear to require only half the amount of GH to cause the
same increase in IGF-1 and to have a given severity (signs and
symptoms) of the disease when they present for diagnosis as do
carriers of the ﬂ-GHR isoform (Schmid et al., 2007). However, con-
ﬂicting data exist with regard to the impact of the d3-GHR muta-
tion on disease severity. In some study populations, the d3-GHR
polymorphism was associated with younger age at diagnosis or
more severe symptoms and more complications (e.g. osteoarthri-
tis, colonic polyps and dolichocolon and possibly type 2 diabetes
(Kamenicky et al., 2009; Wassenaar et al., 2009). When the diagno-
sis of acromegaly is made, knowledge of the GHR genotype is not
expected to inﬂuence therapeutic decisions. However, a recent
study by Bernabeu et al. suggested that the d3-GHR carrier status
could predict a better response to pegvisomant, ﬁndings which
have been challenged by others (Bernabeu et al., 2010; Filopanti
et al., 2012).5. Relevance of the d3-GHR during follow-up of patients with
acromegaly
The main difﬁculty in the care of acromegalic patients is long
term follow-up, as residual disease activity needs to be recognised
and treated. Imaging with MRI is inferior to biochemical testing. As
GH-producing tumours grow slowly and postoperative radiological
changes in the pituitary hamper the interpretation of image, MRI is
able to visualize minor mass increases in only a small number of
patients (Zirkzee et al., 2004). Therefore, to rule out or to rule in
tiny tumour remnants, biochemistry is considered more sensitive
than imaging.
The difﬁculty with biochemical follow-up is that there can be
discrepancies between GH and IGF-1, the classical biochemical
markers of acromegaly. Overall, GH function tests have a better
discriminating readout but IGF-1 appears to be more closely re-
lated to disease activity and correlates more closely with morbidity
and excess mortality in acromegaly both are important (Freda,
2009). On theoretical grounds, assessing GH activity (in part
reﬂected by IGF-1) appears to be more relevant than merely
assessing GH levels. Ideally, IGF-1 should normalise and glucose-
suppressed GH should be low after surgery for acromegaly. Most
often, 1 ng/ml has been used as a cut-off value (Giustina et al.,
2010). However, this ideal scenario is often not clinical reality, with
9–39% of patients showing abnormal GH suppression during oGTT
despite a normal IGF-1 level and 24–62% of patients showing ele-
vated IGF-1 levels despite adequate GH suppression (Freda,
2009). Many diseases may cause inadequate GH suppression, such
as chronic renal insufﬁciency, liver disease, malnutrition or hyper-
glycaemia, to name a few. The GH nadir also seems to be inﬂu-
enced by sex (females having higher values) and body weight, as
a negative correlation with BMI has been described (Ronchi et al.,
2007). To complicate matters further, oGTT is generally unreliable
in patients with diabetes; it should be performed only in patients
with well controlled glycaemia, when the glucose challenge canbe applied at a time of close to normal baseline glucose so that a
glucose rise does occur and is perceived by hypothalamic neurons.
IGF-1 levels are rarely above normal in conditions other than acro-
megaly, but can be elevated in some adolescents. Moreover, mea-
suring IGF-1 remains notoriously difﬁcult, especially since the
less time-consuming modern assays do not try to remove IGF bind-
ing proteins before immunoassay analysis and interferences are
thus more common. In patients with discrepant GH and IGF-1 re-
sults, testing is usually repeated.
Recurrent disease activity is probably more often due to the
growth of remaining tumour cells than to a de novo formation of
another pituitary adenoma. Acromegalic patients with the d3-
GHR genotype could be expected to be at higher risk for clinical
or biochemical recurrence for a given GH level than those with
ﬂ-GHR, because of the enhanced signal transduction transmitted
by the d3-isoform. Bianchi et al. have found that around 70% of
the patients with elevated IGF-1 levels in the presence of appar-
ently normalised GH levels after surgery carried at least one d3 al-
lele (Bianchi et al., 2009). This suggests that GH may be a less
sensitive marker of disease activity in carriers of the d3-GHR poly-
morphism. Moreover, a different (possibly lower) GH nadir on
oGTT may be necessary for such patients, and they probably need
an especially careful and long-term follow-up. It is obvious that the
majority of studies addressing marginal residual disease activity
suffer from confounding by drug treatment efforts to control
excessive GH secretion and activity.6. Relevance of sKlotho during follow-up
We determined the levels of sKlotho with a novel ELISA in 24
consecutive, treatment-naïve acromegalic patients referred for
their ﬁrst surgery (2006–2009) to our institution before and 1–
3 months after transsphenoidal surgery (Yamazaki et al., 2010).
We found that sKlotho levels were markedly increased in relation
to GH excess and declined towards normal levels after surgery (Sze
et al., 2012). In an additional, prospective study we found that
sKlotho was markedly elevated in sera of patients with active acro-
megaly but not in patients with clinically non-functioning pituitary
adenomas, and that sKlotho rapidly decreased towards normal fol-
lowing successful surgical removal of the GH-secreting adenoma
(Neidert et al., 2013). These observations suggested that sKlotho
might be a GH-dependent serum protein. Overall, until 2012, we
assessed serum IGF-1 and sKlotho before and 1–3 months after
surgery in a total of 50 patients with newly diagnosed acromegaly
seen at our institution over the past decade: IGF-1 levels (mean ±
SEM) dropped from 579 ± 32 before to 198 ± 10 ng/ml after sur-
gery, and sKlotho from 4113 ± 415 to 779 ± 63 pg/ml; levels fell
in all patients tested. Levels of sKlotho and IGF-1 appeared to be
similarly dependent on GH. The mechanisms by which elevated
GH leads to excess sKlotho remain unclear. The observation that
sKlotho appears to depend on GH-producing adenomas to a com-
parable extent as IGF-1 raises the possibility of using sKlotho as
an additional serum marker in the long term follow-up of acrome-
galic patients, as sKlotho may reﬂect the activity of GH-producing
tumours.7. Patient examples from the Zurich cohort
Since 2004, we have genotyped 112 patients with acromegaly
(after giving written informed consent to participate in this local
ethics committee-approved study) at our institution; 44 of them
have been reported previously (Schmid et al., 2007). 58 (52%) pa-
tients were homozygous for the ﬂ-GHR (wild type), 43 (38%) pa-
tients had one d3-GHR allele (heterozygous) and 11 (10%)
patients had two d3-GHR alleles (homozygous for the gene
Fig. 1. Changes in IGF-1 and sKlotho in four patients over time. Cases A, C and D
show a marked concordant reduction in serum IGF-1 and sKlotho after transsphe-
noidal surgery, Case B illustrates discordant IGF-1 and sKlotho levels during long-
term follow-up. A detailed description of the patients is included in the text.
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normal population.
We focussed on the potential effect of the d3-GHR on our more
recent cohort of acromegalic patients, all operated by the same
neurosurgeon (R.B) and with histologically proven GH-secreting
adenoma (Bellut et al., 2010). Written informed consent, GHR
genotyping and follow-up data were available for 48 patients with
a diagnosis of acromegaly between 2000 and 2009 (some of whom
had recurrent disease). 24 of these patients were homozygous for
the ﬂ-GHR, 19 patients had one d3-GHR allele and 5 patients had
two d3-GHR alleles. GH (random or nadir during an oGTT) and
IGF-1 levels obtained during follow-up were available for analysis,
and sKlotho measurements were also performed in the majority of
patients in more recent years.
Fig. 1 illustrates the follow-up of four selected individual cases.
Overall, there are concomitant and parallel changes in serum IGF-1
and sKlotho over time in a given individual patient, fairly reliably
reﬂecting disease activity; however, in exceptional situations, lev-
els may be discordant, as illustrated by the patient presented as
case B. It seems that GH-stimulated (hepatic) IGF-1 production is
more strongly attenuated by inﬂammation, oral oestrogens and
pregnancy than GH-stimulated (renal) sKlotho release. Patients A
and C were cured following surgery (IGF-1 remained <300 ng/ml
and sKlotho <1000 pg/ml during follow-up), whereas patient D suf-
fered from recurrent disease activity (discussed below, in the con-
text of GHR).
Case A: This was a 50-year-old female with a long-lasting (in
retrospect, 12 years) history of acromegaly. She had an adenoma
(1.6 ml, tumour volume estimated as in Bellut et al. (2010)) re-
moved, followed by a marked fall in serum IGF-1 and sKlotho.
There was no evidence for pituitary insufﬁciency, and no evidence
for persisting disease activity; GH random values <1 ng/ml were
found. Serum levels of IGF-1 (<300 ng/ml) and sKlotho
(<1000 pg/ml) remained low during follow-up.
Case B: This 28-year-old female presented with a relatively
short history of acromegaly and a huge adenoma (27 ml). Only par-
tial surgical debulking was feasible, and she remained with a tu-
mour remnant and active acromegaly. Of note, discordant IGF-1
and sKlotho levels were found in this patient on several occasions:
ﬁrst, she developed bacterial coxitis in the immediate postopera-
tive period; IGF-1 fell transiently into the normal range (to
<300 ng/ml) while sKlotho remained high (7900 pg/ml). She was
then treated with radiotherapy, followed by sandostatin LAR (SS),
and received hormone replacement therapy (including oral oestro-
gens) for subsequent pituitary failure. There was semi-concordant
control of IGF-1 (satisfactory, <300 ng/ml) and sKlotho (partial re-
sponse, levels at 2000 pg/ml). Later, during gonadotropin-induced
pregnancy, SS was paused, resulting in essentially unchanged
IGF-1 levels (as anticipated, considering the characteristic sponta-
neous drop in IGF-1 during pregnancy in patients with acromegaly
but in a rise in sKlotho up toP4000 pg/ml (last two points in graph
1B) (Wiesli et al., 2006).
Case C: This 37-year-old male patient presented with an ade-
noma (4.2 ml) which was, in retrospect, only partially removed
by the ﬁrst surgery. A second operation resulted in a further de-
crease in serum IGF-1 and sKlotho, to disappearance of disease
activity and to a GH suppressible to <1 ng/ml on oGTT (Fig. 2A)
at the time of writing, 5 years after the patients’ ﬁrst surgery.
Case D: This 40-year-old lady had apparently successful removal
of an adenoma (2.5 ml) for up to two years after surgery. She car-
ried one d3-GHR allele. Twenty months postoperatively, she sup-
pressed GH from a baseline of 7.16 ng/ml to a nadir of 0.56 ng/ml
during oGTT; IGF-1 was within the high-normal range at that time.
The shape of the GH curve suggested that normal rather than ade-
nomatous GH-secreting cells contributed to the bulk of GH in the
patients’ serum. Thirty months postoperatively, IGF-1 and sKlothobegan to increase, and on repeat oGTT, the GH nadir was 0.84 ng/
ml. 43 months postoperatively, IGF-1 had further increased, and
GH suppressed from a baseline of 3.05 ng/ml to a minimum of only
1.02 ng/ml on oGTT testing (Fig. 2B). Thus, according to standard
guidelines, she had recurrent acromegaly. An MRI of the pituitary
failed to show any evidence of a pituitary tumour. Because the pa-
tient had increasing symptoms of acromegaly, treatment with
cabergoline was begun 80 months after surgery, resulting in
decreasing IGF-1 and sKlotho levels with partial relief of
symptoms.
Fig. 2. GH suppression during oGTT over time in a patient (A) with residual adenoma and improved GH suppression during oGTT after an additional operation, and follow-up
of a patient (B) carrying one d3-GHR and recurrent disease activity.
286 S. Kohler et al. / General and Comparative Endocrinology 188 (2013) 282–287Among our 48 patients with a diagnosis of acromegaly between
2000 and 2009 and close follow-up, 45 had obvious ﬁndings (as
judged by four concordant criteria, namely (1) clinical, (2) GH-lev-
els, (3) IGF-1 levels and (4) imaging) in favour of or against persis-
tent disease activity. As stated above, 24 of these 48 patients were
homozygous for the ﬂ-GHR, 19 patients had one d3-GHR alleles
and 5 patients had two d3-GHR alleles. One of the patients with
an obvious residual tumour mass (an adenoma remnant in the cav-
ernous sinus) and persistent disease activity and elevated IGF-1
(values >500 ng/ml) occasionally reached random GH values of
<1 ng/ml; he had two d3-GHR alleles. Three of the 48 patients
had ambiguous ﬁndings during follow-up, despite initial postoper-
ative GH suppression <1 ng/ml and clinical evidence for remission
of acromegaly; all 3 of them carried at least one d3-GHR allele.
The 1st patient is described in case D (she was heterozygous for
the d3-GHR allele), in her case, a remnant tumour ﬁnally became
detectable on MRI after 8 years of follow-up (she is currently will-
ing to undergo repeat surgery). Fig. 2B demonstrates the progres-
sive lack of GH suppression during oGTT over time in this
patient. Fig. 2A, in comparison, illustrates physiological GH sup-
pression during oGTT after repeated transsphenoidal surgeries in
a patient with initially evident residual adenoma (patient shown
in panel C of Fig. 1).
The 2nd patient, a 45-year-old man with two d3-GHR alleles,
developed recurrent symptoms of acromegaly after 1 year of fol-
low-up. He had no visible residual tumour on MRI postoperatively
and GH suppressed to a nadir of 0.2 ng/ml during postoperative
oGTT, but IGF-1 gradually increased above the upper limit of nor-
mal. He complained of debilitating joint pain, a subsequent pitui-
tary MRI revealed an intrasellar mass suspicious for tumour
regrowth (questionable, not conﬁrmed in subsequent imaging).
The 3rd patient, a 52-year-old woman with one d3-GHR allele,
suppressed GH on oGTT to 0.52 ng/ml 6 months and to 0.63 ng/ml
31 months after surgery. However, IGF-1 gradually increased and
pituitary MRI suggested a remnant adenoma. The patient herself,
however, denied recurrent symptoms of acromegaly.
a-Klotho has been found to be a central player in calcium and
phosphate homoeostasis (Hu et al., 2013). As compared to intra-
and paracrine FGFs, FGF23 as binding partner of a transmembrane
a-Klotho-containing complex emerged later during evolution. FGFs
are a large family of peptides which, together with their receptor
tyrosine kinases (FGFRs) comprise a signalling system that controls
development and homoeostasis. The endocrine (FGF19) subfamily
(including FGF19, FGF 21 and FGF23) appears to be vertebrate spe-
ciﬁc and is characterized by a lack of a heparin binding domain sothat they escape capturing by the nearby extracellular matrix and
reach the circulation (Itoh and Ornitz, 2011). Moreover, endocrine
FGFs do not require heparan sulfate proteoglycans for efﬁcient
FGFR interaction; however, they need transmembrane klotho(s)
as co-receptors instead. Considering evolution, it is obvious that
the (later) development of a bony endoskeleton in higher verte-
brates and adaptation to terrestrial life set increasingly higher de-
mands and required additional signals (for and from bone) to
ensure and regulate energy homeostasis, metabolism, nutrient
and ion and mineral handling, and to communicate with intestine
(for absorption) and the kidney (for excretion) (Hu et al., 2013).
Two Fgf-like genes, egl-17 and let-756, and two Klotho-like genes,
klo-1 and klo-2 have been identiﬁed in the nematode Caenorhabdi-
tis elegans (Huang and Stern, 2005; Polanska et al., 2011). In the
nematode C. elegans, the corresponding KLO-1 and KLO-2 proteins
are expressed in the intestine, in the excretory canal and in the
hypodermis (Polanska et al., 2011). Unlike the vertebrate Klotho
proteins, KLO-1 and KLO-2 in nematodes lack a transmembrane
domain. The ancestral ‘‘truncated’’ Klotho forms in nematodes
and in Drosophila contain only one KL domain whereas the full
length transmembrane vertebral Klothos are composed of two KL
domains. In men, the alternatively spliced form for the shorter, di-
rectly secreted isoform, is reminiscent of these genes (Matsumura
et al., 1998)
IGF-1 and sKlotho are both relatively abundant in the circula-
tion; both of them are regulated by GH. In the case of IGF-1, there
is fairly good evidence that it mediates some actions of GH and that
there is a negative feedback. Indeed, there is pituitary expression in
bony ﬁsh and in humans, and it may well be that there is not only a
negative feedback from circulating (endocrine) IGF-1 but also form
locally produced (paracrine or autocrine) IGF-1 (Guler et al., 1989;
Eppler et al., 2007; Jevdjovic et al., 2007). In the case of Klotho,
there is a lack of data to show whether it mediates actions of GH,
and there is no proof for receptors in the pituitary which could
mediate a negative feedback. Still, the expression of Klotho has
been demonstrated in the pituitary, in the original paper on its dis-
covery at the gene level as well as by immunohistochemistry in the
human pituitary (Kuro-o et al., 1997; Neidert et al., 2013).
8. Conclusion
Our data, and in particular the 3 patients with increasing IGF-1
levels despite initial postoperative GH suppression <1 ng/ml de-
scribed above, suggest that individuals with the d3-GHR polymor-
phism could indeed be at higher risk for recurrence of acromegaly
S. Kohler et al. / General and Comparative Endocrinology 188 (2013) 282–287 287and have a lower chance of achieving IGF-I normalization after
therapy, as suggested previously (Mercado et al., 2008). Although
GH levels remained relatively low in the 3 patients, disease activ-
ity, as well as IGF-1 and sKlotho levels, increased. Possibly, a lower
GH nadir during oGTT needs to be deﬁned for such patients. In our
view, GH actions (i.e. clinical symptoms and signs, IGF-1 and sKlo-
tho) are more important than GH levels when estimating the (neg-
ative) impact of potential remnant adenomas.
At our institution, we do not use standardised questionnaires
(or scores) but rather focus on the severity (over time) of the per-
sonal leading symptoms and signs in the particular individual pa-
tients we care for. However, we fully concur with Neggers et al.
that additional markers beyond IGF-1 are required to assess resid-
ual disease activity in patients with acromegaly (Neggers et al.,
2012).
It is an obvious limitation of our study that the number of pa-
tients with a suspicion for small tumour remnants and question-
able residual disease activity despite initial GH suppression
<1 ng/ml is quite small, so that a meaningful statistical evaluation
has not been feasible so far. Thus, future studies (of larger size and
with longer follow-up) will need to investigate whether the d3-
GHR really is clinically relevant for follow-up and management
decisions in patients with acromegaly. In addition, we propose that
sKlotho may be a useful marker for the long-term follow-up of pa-
tients with acromegaly, as it seems to reﬂect the activity of GH-
producing tumours, and we hope this will be tested in more detail
in a larger number of patients.References
Akimoto, T., Yoshizawa, H., Watanabe, Y., et al., 2012. Characteristics of urinary and
serum soluble Klotho protein in patients with different degrees of chronic
kidney disease. BMC Nephrol. 13, 155.
Akimoto, T., Kimura, T., Watanabe, Y., et al., 2013. The impact of nephrectomy and
renal transplantation on serum levels of soluble Klotho protein. Transplant.
Proc. 45 (1), 134–136.
Alexander, R.T., Woudenberg-Vrenken, T.E., Buurman, J., et al., 2009. Klotho
prevents renal calcium loss. J. Am. Soc. Nephrol. 20 (11), 2371–2379.
Asai, O., Nakatani, K., Tanaka, T., et al., 2012. Decreased renal alpha-Klotho
expression in early diabetic nephropathy in humans and mice and its possible
role in urinary calcium excretion. Kidney Int. 81 (6), 539–547.
Bellut, D., Hlavica, M., Schmid, C., et al., 2010. Intraoperative magnetic resonance
imaging-assisted transsphenoidal pituitary surgery in patients with
acromegaly. Neurosurg. Focus 29 (4), E9.
Bernabeu, I., Alvarez-Escola, C., Quinteiro, C., et al., 2010. The exon 3-deleted growth
hormone receptor is associated with better response to pegvisomant therapy in
acromegaly. J. Clin. Endocrinol. Metab. 95 (1), 222–229.
Bianchi, A., Giustina, A., Cimino, V., et al., 2009. Inﬂuence of growth hormone
receptor d3 and full-length isoforms on biochemical treatment outcomes in
acromegaly. J. Clin. Endocrinol. Metab. 94 (6), 2015–2022.
Blum, W.F., Machinis, K., Shavrikova, E.P., et al., 2006. The growth response to
growth hormone (GH) treatment in children with isolated GH deﬁciency is
independent of the presence of the exon 3-minus isoform of the GH receptor. J.
Clin. Endocrinol. Metab. 91 (10), 4171–4174.
Bougneres, P., 2010. The exon-3 deletion of the growth hormone receptor (GHR)
gene still has a limited impact in clinical endocrinology. J. Clin. Endocrinol.
Metab. 95 (1), 56–59.
Chang, Q., Hoefs, S., van der Kemp, A.W., et al., 2005. The beta-glucuronidase klotho
hydrolyzes and activates the TRPV5 channel. Science 310 (5747), 490–493.
Dos Santos, C., Essioux, L., Teinturier, C., et al., 2004. A common polymorphism of
the growth hormone receptor is associated with increased responsiveness to
growth hormone. Nat. Genet. 36 (7), 720–724.
Eppler, E., Shved, N., Moret, O., et al., 2007. IGF-I is distinctly located in the bony ﬁsh
pituitary as revealed for Oreochromis niloticus, the Nile tilapia, using real-time
RT-PCR, in situ hybridisation and immunohistochemistry. Gen. Comp.
Endocrinol. 150 (1), 87–95.
Filopanti, M., Olgiati, L., Mantovani, G., et al., 2012. Growth hormone receptor
variants and response to pegvisomant in monotherapy or in combination with
somatostatin analogs in acromegalic patients: a multicenter study. J. Clin.
Endocrinol. Metab. 97 (2), E165–E172.
Freda, P.U., 2009. Monitoring of acromegaly: what should be performed when GH
and IGF-1 levels are discrepant? Clin. Endocrinol. (Oxf) 71 (2), 166–170.
Giustina, A., Chanson, P., Bronstein, M.D., et al., 2010. A consensus on criteria for
cure of acromegaly. J. Clin. Endocrinol. Metab. 95 (7), 3141–3148.Guler, H.P., Schmid, C., Zapf, J., et al., 1989. Effects of recombinant insulin-like
growth factor I on insulin secretion and renal function in normal human
subjects. Proc. Natl. Acad. Sci. U.S.A. 86 (8), 2868–2872.
Hu, M.C., Shi, M., Zhang, J., et al., 2011. Klotho deﬁciency causes vascular
calciﬁcation in chronic kidney disease. J. Am. Soc. Nephrol. 22 (1), 124–136.
Hu, M.C., Shiizaki, K., Kuro-o, M., et al., 2013. Fibroblast growth factor 23 and
Klotho: physiology and pathophysiology of an endocrine network of mineral
metabolism. Annu. Rev. Physiol. 75, 503–533.
Huang, P., Stern, M.J., 2005. FGF signaling in ﬂies and worms: more and more
relevant to vertebrate biology. Cytokine Growth Factor Rev. 16 (2), 151–158.
Imura, A., Iwano, A., Tohyama, O., et al., 2004. Secreted Klotho protein in sera and
CSF: implication for post-translational cleavage in release of Klotho protein
from cell membrane. FEBS Lett. 565 (1–3), 143–147.
Ito, N., Fukumoto, S., Taguchi, M., et al., 2007. Fibroblast growth factor (FGF)23 in
patients with acromegaly. Endocr. J. 54 (3), 481–484.
Itoh, N., Ornitz, D.M., 2011. Fibroblast growth factors: from molecular evolution to
roles in development, metabolism and disease. J. Biochem. 149 (2), 121–130.
Jevdjovic, T., Bernays, R.L., Eppler, E., 2007. Insulin-like growth factor-I mRNA and
peptide in the human anterior pituitary. J. Neuroendocrinol. 19 (5), 335–341.
Kamenicky, P., Dos Santos, C., Espinosa, C., et al., 2009. D3 GH receptor
polymorphism is not associated with IGF1 levels in untreated acromegaly.
Eur. J. Endocrinol. 161 (2), 231–235.
Koh, N., Fujimori, T., Nishiguchi, S., et al., 2001. Severely reduced production of
klotho in human chronic renal failure kidney. Biochem. Biophys. Res. Commun.
280 (4), 1015–1020.
Kuro-o, M., Matsumura, Y., Aizawa, H., et al., 1997. Mutation of the mouse klotho
gene leads to a syndrome resembling ageing. Nature 390 (6655), 45–51.
Kurosu, H., Yamamoto, M., Clark, J.D., et al., 2005. Suppression of aging in mice by
the hormone Klotho. Science 309 (5742), 1829–1833.
Kurosu, H., Ogawa, Y., Miyoshi, M., et al., 2006. Regulation of ﬁbroblast growth
factor-23 signaling by klotho. J. Biol. Chem. 281 (10), 6120–6123.
Li, S.A., Watanabe, M., Yamada, H., et al., 2004. Immunohistochemical localization of
Klotho protein in brain, kidney, and reproductive organs of mice. Cell Struct.
Funct. 29 (4), 91–99.
Matsumura, Y., Aizawa, H., Shiraki-Iida, T., et al., 1998. Identiﬁcation of the human
klotho gene and its two transcripts encoding membrane and secreted klotho
protein. Biochem. Biophys. Res. Commun. 242 (3), 626–630.
Mercado, M., Gonzalez, B., Sandoval, C., et al., 2008. Clinical and biochemical impact
of the d3 growth hormone receptor genotype in acromegaly. J. Clin. Endocrinol.
Metab. 93 (9), 3411–3415.
Neggers, S.J., Biermasz, N.R., van der Lely, A.J., 2012. What is active acromegaly and
which parameters do we have? Clin. Endocrinol. (Oxf) 76 (5), 609–614.
Neidert, M.C., Sze, L., Zwimpfer, C., et al., 2013. Soluble alpha-Klotho: a novel serum
biomarker for the activity of GH-producing pituitary adenomas. Eur. J.
Endocrinol. 168 (4), 575–583.
Pantel, J., Machinis, K., Sobrier, M.L., et al., 2000. Species-speciﬁc alternative splice
mimicry at the growth hormone receptor locus revealed by the lineage of
retroelements during primate evolution. J. Biol. Chem. 275 (25), 18664–18669.
Polanska, U.M., Edwards, E., Fernig, D.G., et al., 2011. The cooperation of FGF
receptor and Klotho is involved in excretory canal development and regulation
of metabolic homeostasis in Caenorhabditis elegans. J. Biol. Chem. 286 (7), 5657–
5666.
Ronchi, C.L., Arosio, M., Rizzo, E., et al., 2007. Adequacy of current postglucose GH
nadir limit (<1 microg/l) to deﬁne long-lasting remission of acromegalic
disease. Clin. Endocrinol. (Oxf) 66 (4), 538–542.
Schmid, C., Krayenbuehl, P.A., Bernays, R.L., et al., 2007. Growth hormone (GH)
receptor isoform in acromegaly: lower concentrations of GH but not insulin-like
growth factor-1 in patients with a genomic deletion of exon 3 in the GH
receptor gene. Clin. Chem. 53 (8), 1484–1488.
Semba, R.D., Cappola, A.R., Sun, K., et al., 2011. Plasma klotho and mortality risk in
older community-dwelling adults. J. Gerontol. A Biol. Sci. Med. Sci. 66 (7), 794–
800.
Sze, L., Bernays, R.L., Zwimpfer, C., et al., 2012. Excessively high soluble Klotho in
patients with acromegaly. J. Intern. Med. 272 (1), 93–97.
Urakawa, I., Yamazaki, Y., Shimada, T., et al., 2006. Klotho converts canonical FGF
receptor into a speciﬁc receptor for FGF23. Nature 444 (7120), 770–774.
Wan, J., Atzmon, G., Hwang, D., et al., 2013. Growth hormone receptor (GHR) exon 3
polymorphism status detection by dual-enzyme-linked immunosorbent assay
(ELISA). J. Clin. Endocrinol. Metab. 98 (1), E77–E81.
Wassenaar, M.J., Biermasz, N.R., Pereira, A.M., et al., 2009. The exon-3 deleted
growth hormone receptor polymorphism predisposes to long-term
complications of acromegaly. J. Clin. Endocrinol. Metab. 94 (12), 4671–4678.
Wiesli, P., Zwimpfer, C., Zapf, J., et al., 2006. Pregnancy-induced changes in insulin-
like growth factor I (IGF-I), insulin-like growth factor binding protein 3 (IGFBP-
3), and acid-labile subunit (ALS) in patients with growth hormone (GH)
deﬁciency and excess. Acta Obstet. Gynecol. Scand. 85 (8), 900–905.
Yamazaki, Y., Imura, A., Urakawa, I., et al., 2010. Establishment of sandwich ELISA
for soluble alpha-Klotho measurement: age-dependent change of soluble alpha-
Klotho levels in healthy subjects. Biochem. Biophys. Res. Commun. 398 (3),
513–518.
Zirkzee, E.J., Corssmit, E.P., Biermasz, N.R., et al., 2004. Pituitary magnetic resonance
imaging is not required in the postoperative follow-up of acromegalic patients
with long-term biochemical cure after transsphenoidal surgery. J. Clin.
Endocrinol. Metab. 89 (9), 4320–4324.
